Nishikawa, M., Inoue, A., Ohnishi, T., Yano, H., Kanemura, Y., Kohno, S., . . . Kunieda, T. (2021). CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma. Cancer Med.
Styl cytowania ChicagoNishikawa, Masahiro, et al. "CD44 Expression in the Tumor Periphery Predicts the Responsiveness to Bevacizumab in the Treatment of Recurrent Glioblastoma." Cancer Med 2021.
Styl cytowania MLANishikawa, Masahiro, et al. "CD44 Expression in the Tumor Periphery Predicts the Responsiveness to Bevacizumab in the Treatment of Recurrent Glioblastoma." Cancer Med 2021.
Uwaga: Te cytaty mogą odróżniać się od wytycznej twojego fakultetu..